Trial adds SBP-101 to standard chemo for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic ductal adenocarcinoma confirmed by biopsy or body-fluid test
- Your metastatic disease was diagnosed within the last 3 months and you have not yet been treated for it
- You can have standard treatment with gemcitabine plus nab-paclitaxel, and you have CT or MRI evidence of measurable tumors
- You are an adult (18+) with an overall good performance status (ECOG 0–1) and expected survival of at least 3 months
- Your blood, liver, and kidney tests are adequate, and your heart rhythm test (ECG QTc) is within the trial’s limits
- You can give signed informed consent and, if you can become pregnant, you meet pregnancy test and contraception rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
This study tests a new treatment approach for advanced pancreatic cancer in patients who have never received chemotherapy for their advanced disease. The trial aims to evaluate whether this new strategy can help control the cancer and improve outcomes.
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.